Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedImmune for sale

Executive Summary

The biotechnology firm announces April 12 that it is exploring a possible sale. MedImmune has a market capitalization of over $10 billion and markets the influenza vaccine FluMist, the respiratory syncytial virus treatment Synagis (palivizumab) and the cytoprotective agent Ethyol (amifostine). A BLA for the Synagis follow-on Numax is planned for this year. The firm already has relationships with Merck and GlaxoSmithKline, which use the firm's "virus-like particle technology" in the production of HPV vaccines Gardasil and Cervarix. Pfizer has also expressed an interest in significantly boosting its biologics portfolio via acquisition...

You may also be interested in...



Astra Wins MedImmune Auction; $15.6 Billion Price Tag Raises Eyebrows

AstraZeneca's move to bolster its biologics portfolio through the acquisition of MedImmune for roughly $15.6 billion illustrates the increasingly high stakes of mergers in the biotech space

Biohaven’s Nurtec May Be First Migraine Drug For Acute Treatment And Prevention

Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.

US FDA Offers More Advice On Mid-Trial Changes For Pandemic-Impacted Studies

A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.

UsernamePublicRestriction

Register

PS048257

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel